These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25361994)

  • 21. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimated costs of pivotal trials for U.S. Food and Drug Administration-approved cancer drugs, 2015-2017.
    Hsiue EH; Moore TJ; Alexander GC
    Clin Trials; 2020 Apr; 17(2):119-125. PubMed ID: 32114790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of drugs approved in Japan without conducting confirmatory clinical trials.
    Izuka S; Matsumaru N; Tsukamoto K
    J Clin Pharm Ther; 2021 Dec; 46(6):1582-1590. PubMed ID: 34250620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. End points and United States Food and Drug Administration approval of oncology drugs.
    Johnson JR; Williams G; Pazdur R
    J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent trends for drug lag in clinical development of oncology drugs in Japan: does the oncology drug lag still exist in Japan?
    Maeda H; Kurokawa T
    Int J Clin Oncol; 2015 Dec; 20(6):1072-80. PubMed ID: 25837976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.
    Prasad V; Kim C; Burotto M; Vandross A
    JAMA Intern Med; 2015 Aug; 175(8):1389-98. PubMed ID: 26098871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
    Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
    Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strength of statistical evidence for the efficacy of cancer drugs: a Bayesian reanalysis of randomized trials supporting Food and Drug Administration approval.
    Pittelkow MM; Linde M; de Vries YA; Hemkens LG; Schmitt AM; Meijer RR; van Ravenzwaaij D
    J Clin Epidemiol; 2024 Oct; 174():111479. PubMed ID: 39047916
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
    Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
    JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Belgian observational survival data (incidence years 2004-2017) and expenditure for innovative oncology drugs in twelve cancer indications.
    Neyt M; Devos C; Thiry N; Silversmit G; De Gendt C; Van Damme N; Castanares-Zapatero D; Hulstaert F; Verleye L
    Eur J Cancer; 2023 Mar; 182():23-37. PubMed ID: 36731327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression-free survival in oncology: Caveat emptor!
    Bergmann TK; Christensen MMH; Henriksen DP; Haastrup MB; Damkier P
    Basic Clin Pharmacol Toxicol; 2019 Mar; 124(3):240-244. PubMed ID: 30417586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Approving molecularly targeted drugs: different approval processes for cytotoxic agents.
    Sasahara Y; Narimatsu H; Fukao A; Yoshioka T
    Int J Clin Oncol; 2016 Oct; 21(5):1004-1013. PubMed ID: 27105626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics of pharmacogenomics/biomarker-guided clinical trials for regulatory approval of anti-cancer drugs in Japan.
    Ishiguro A; Yagi S; Uyama Y
    J Hum Genet; 2013 Jun; 58(6):313-6. PubMed ID: 23657427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monitoring evidence on overall survival benefits of anticancer drugs approved by the European Medicines Agency between 2009 and 2015.
    Grössmann N; Robausch M; Rosian K; Wild C; Simon J
    Eur J Cancer; 2019 Mar; 110():1-7. PubMed ID: 30735832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020.
    Zhang Y; Naci H; Wagner AK; Xu Z; Yang Y; Zhu J; Ji J; Shi L; Guan X
    JAMA Netw Open; 2022 Aug; 5(8):e2225973. PubMed ID: 35947385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time.
    Thomson S; Witzke N; Gyawali B; Delos Santos S; Udayakumar S; Cardone C; Cheung MC; Chan KKW
    Eur J Cancer; 2021 Jun; 150():203-210. PubMed ID: 33932727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Publicly accessible evidence of health-related quality of life benefits associated with cancer drugs approved by the European Medicines Agency between 2009 and 2015.
    Grössmann N; Robausch M; Rothschedl E; Wild C; Simon J
    Eur J Cancer; 2020 Apr; 129():23-31. PubMed ID: 32120272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.